HOME >> MEDICINE >> NEWS
12-month study demonstrated tolerability and efficacy of Daytrana

SAN DIEGO MAY 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that DAYTRANATM (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association (APA) annual meeting in San Diego.

"We documented that children with ADHD experienced effective ADHD treatment with use of DAYTRANA for 12 months, sustaining the improvements in their ability to maintain focus and concentration," said investigator Oscar Bukstein, M.D., M.P.H ,Associate Professor of Psychiatry, University of Pittsburgh School of Medicine. "More importantly, Daytrana maintained a favorable safety profile, meeting the study's primary endpoint, and demonstrating an incidence of adverse events that is consistent with previous trials and other stimulants in this class."

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths 10 mg, 15 mg, 20 mg and 30 mg all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects.

Bukstein added, "DAYTRANA's novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their children's changing schedules."

This study was an open-label extension of four clinical trials. T
'"/>

Contact: Marion E. Glick
212-601-8273
Porter Novelli
23-May-2007


Page: 1 2 3

Related medicine news :

1. $1.5 billion needed to ensure 12-month stockpile of pediatric vaccines
2. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
3. Penn study finds pro-death proteins required to regulate healthy immune function
4. New study shows promise in reducing surgical risks associated with surgical bleeding
5. New study counts the economic cost of persistent pain in Australia
6. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
7. Most seniors now have drug coverage, U-M study shows
8. To gain muscle and lose fat, drink milk: study
9. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
10. Even older women at high risk have little interest in being tested for HIV, study finds
11. Metabolic study in mice could lead to good cholesterol boosters

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: month study demonstrated tolerability and efficacy Daytrana

(Date:11/28/2014)... York, NY (PRWEB) November 28, 2014 ... Salvage ( http://www.rustysautosalvage.com ), one of the nation's leading ... junk and salvage vehicles to be more competitive and ... customer’s lives during this festive time of year. , ... many car owners across the US also deal with ...
(Date:11/28/2014)... Novatus, a leading provider of contract ... provides customers with greater reporting capabilities, more searchable ... we continue to evolve and grow the Novatus ... improved performance in response to requests from our ... the enhancements that we have made to Advanced ...
(Date:11/28/2014)... November 28, 2014 Dr. Andrew Campbell, ... , announced the expansion of Quintessa Aesthetic Center into ... be located at W307 N1497 Golf Road in Suite ... to Dr. Campbell, the new Delafield location will offer ... for patients, including: Botox, filler injectables , micro ...
(Date:11/28/2014)... 28, 2014 Dr. Paul Vitenas, one of the ... Glitter & Glow Holiday Event for those in the area that ... his practice. Glitter & Glow will take place on December 11, ... location in the heart of Houston at 4208 Richmond Ave. ... hope that you will come and celebrate the season with us ...
(Date:11/28/2014)... 2014 Written and narrated by award winning ... releases the “The Happiest Man In the World: Life ... of how and why Project C.U.R.E. came to be. , ... Josie and the Reverend Richard W. Jackson, Dr. Jackson exceeded ... 30, but realized that he wasn’t happy. Prompted by this ...
Breaking Medicine News(10 mins):Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2
(Date:11/26/2014)... WASHINGTON and NEW YORK ... 2014 As the leading distributor of market ... a new research report by IQ4I Research and Consultancy ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast ...
(Date:11/26/2014)...  At the American Dental Association,s Annual Meeting in ... Kerr Group was honored to be part of the ... to see and test the Best of Class winners ... on the latest developments in dental technology. This year, ... CariVu Caries Detection Device and Kerr Demi ™  ...
(Date:11/26/2014)... , Nov. 25, 2014 Reinforcing its ... Philips (NYSE: PHG AEX: PHIA) ... Drug Administration (FDA) for its IQon Spectral CT ... This first-of-its kind technology adds a new dimension to ... the ability to characterize structures based on their material ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
Cached News: